Janus Henderson Investors US LLC has recently announced that it has increased stake in Olema Pharmaceuticals Inc. (NASDAQ:OLMA) by 2.27%. After grabbing 3.4 million shares, the institutional investor is now in possession of 75554.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.40% having worth around $9.75 million. Moreover, The Vanguard Group, Inc. increased its share by 61160.0 to have a control over 1.46 million shares. And Kynam Capital Management LP raised its holdings to 1.15 million shares by acquiring 1.4 million shares or 3.46% of the stake.
Olema Pharmaceuticals Inc. (OLMA) concluded trading on 01/12/23 at a closing price of $4.01, with 0.79 million shares of worth about $3.18 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.83% during that period and on Thursday the price saw a gain of about 2.30%. Currently the company’s common shares owned by public are about 40.04M shares, out of which, 37.70M shares are available for trading.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 6 analysts are covering the OLMA stock and their offered price forecasts bring an average price target of $13.25. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $16.00 and could fall to a lowest price of $10.00. The stock’s current price level is 69.74% above of average price target set by the analysts, while a rise to estimated low would result in gain of 59.9% for the stock. However, touching the estimated high of $16.00 would mean a gain of 74.94% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 9 times over the past 12 months. They bought 270,504 shares in 7 of the transactions. In 2 selling transactions, insiders dumped 10,504 shares.
Vanguard Total Stock Market Index, Janus Henderson Global Life Scien, and Janus Henderson Capital Funds Plc are the top 3 mutual funds which are holding stakes in Olema Pharmaceuticals Inc. Vanguard Total Stock Market Index is currently holding 1.01 million shares of worth totaling $2.89 million. The company recently came buying 0.0 shares which brought its stake up to 2.49% of the company’s outstanding shares. Janus Henderson Global Life Scien sold 7775.0 shares, after which its hold over company’s outstanding shares shrunk to 1.83%, leaving 0.74 million shares with the mutual fund that have a worth of about $2.13 million. Janus Henderson Capital Funds Plc, after selling 0.65 million shares, have now control over 1.60% of the stake in the company. It holds 229.0 shares of worth $1.86 million.
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) started trading at $3.75, below -$0.17 from concluding price of the previous day. However, the stock later moved at a day high price of 4.0500, or with a gain of 2.30%. Stock saw a price change of 45.82% in past 5 days and over the past one month there was a price change of 68.49%. Year-to-date (YTD), OLMA shares are showing a performance of 63.67% which decreased to -45.29% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.00 but also hit the highest price of $7.41 during that period. The average intraday trading volume for Olema Pharmaceuticals Inc. shares is 121.90K. The stock is currently trading 51.66% above its 20-day simple moving average (SMA20), while that difference is up 41.10% for SMA50 and it goes to 16.17% higher than SMA200.
Janus Henderson Investors US LLC acquired 3.4 million shares of Olema Pharmaceuticals Inc. having value of about $9.75 million. Data submitted at the U.S SEC by Janus Henderson Investors US LLC revealed that the firm now holds 75554.0 shares in the company valued at close to $302971.54, or have control over 2.27% stake in the company. Olema Pharmaceuticals Inc. (NASDAQ: OLMA) currently have 40.04M outstanding shares and institutions hold larger chunk of about 84.60% of that. Holding of mutual funds in the company is about 25.31% while other institutional holders and individual stake holders have control over 63.66% and 15.85% of the stake respectively.
The stock has a current market capitalization of $156.59M. It has posted earnings per share of -$2.51 in the same period. It has Quick Ratio of 17.90 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OLMA, volatility over the week remained 14.35% while standing at 11.18% over the month.
Analysts are in expectations that Olema Pharmaceuticals Inc. (OLMA) stock would likely to be making an EPS of -$0.77 in the current quarter, while forecast for next quarter EPS is -$0.76 and it is -$3.23 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.9 which is -$0.68 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.45 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -188.80% while it is estimated to decrease by -13.50% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Canaccord Genuity on July 06, 2022 offering a Buy rating for the stock and assigned a target price of $16 to it. Coverage by H.C. Wainwright stated Olema Pharmaceuticals Inc. (OLMA) stock as a Buy in their note to investors on June 09, 2022, suggesting a price target of $12 for the stock. Stock get an Overweight rating from JP Morgan on December 14, 2020.
